成年早期与中晚年体脂及身高与前列腺癌风险和死亡的关系
结果显示基线 BMI、腰围、腰臀比和身高与晚期前列腺癌或死亡相关,而成年早期 BMI 无显著关联。维持健康体重可能有助于预防晚期前列腺癌。
要点
- 基线 BMI≥35.0 与 21–22.9 kg/m2 相比,前列腺癌死亡 HR=1.52(95%CI 1.12–2.07)。
- 成年早期 BMI<25.0 且基线 BMI≥30.0 者,前列腺癌死亡风险高 27%(95%CI 9%–49%)。
- 身高≥1.90 m 与 <1.65 m 相比,晚期或限制性晚期前列腺癌及死亡风险高 33%–56%。
核心结论
- 中晚年总脂肪和中心性肥胖及身高与晚期前列腺癌风险和死亡相关。
- 成年早期肥胖与晚期前列腺癌风险和死亡无显著关联。
- 维持健康体重可能有助于预防晚期前列腺癌。
研究设计与样本
- 病例包括 4762 例晚期、2915 例限制性晚期、9489 例高级别和 3027 例前列腺癌死亡。
- 采用 Cox 比例风险模型计算研究特异性 HR 和 95%CI,并用随机效应模型合并。
主要发现
- 基线 BMI≥35.0 与 21–22.9 kg/m2 相比,晚期前列腺癌 HR=1.30(95%CI 0.95–1.78),前列腺癌死亡 HR=1.52(95%CI 1.12–2.07)。
- 成年早期 BMI<25.0 且基线 BMI≥30.0 与成年早期 BMI<25.0 且基线 BMI<30.0 相比,前列腺癌死亡风险高 27%(95%CI 9%–49%)。
- 基线腰围≥110 cm 与 <90 cm 相比,高级别前列腺癌风险增加 14%–16%,前列腺癌死亡风险增加 20%–39%。
- 基线腰臀比≥1.00 与 <0.90 相比,高级别前列腺癌风险增加 14%–16%,前列腺癌死亡风险增加 20%–39%。
- 身高≥1.90 m 与 <1.65 m 相比,晚期或限制性晚期前列腺癌及前列腺癌死亡风险增加 33%–56%。
关键数值与推荐
- 晚期前列腺癌定义:T4/N1/M1 或前列腺癌死亡。
- 限制性晚期前列腺癌定义:同晚期,但排除导致死亡的局限期癌症。
- 高级别前列腺癌:原文未报告具体分级标准。
临床怎么用
- 临床评估前列腺癌风险时可关注中晚年 BMI、腰围和腰臀比。
- 对中晚年肥胖男性,尤其是成年早期瘦而中年后肥胖者,应加强前列腺癌筛查和体重管理宣教。
- 身高较高男性可能需关注晚期前列腺癌风险,但需结合其他风险因素综合判断。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advanced prostate cancer etiology is poorly understood. Few studies have examined associations of anthropometric factors (e.g. early adulthood obesity) with advanced prostate cancer risk. PATIENTS AND METHODS: We carried out pooled analyses to examine associations between body fatness, height, and prostate cancer risk. Among 830 772 men, 51 734 incident prostate cancer cases were identified, including 4762 advanced (T4/N1/M1 or prostate cancer deaths) cases, 2915 advanced restricted (same as advanced, but excluding localized cancers that resulted in death) cases, 9489 high-grade cases, and 3027 prostate cancer deaths. Cox proportional hazards models were used to calculate study-specific hazard ratios (HR) and 95% confidence intervals (CI); results were pooled using random effects models. RESULTS: No statistically significant associations were observed for body mass index (BMI) in early adulthood for advanced, advanced restricted, and high-grade prostate cancer, and prostate cancer mortality. Positive associations were shown for BMI at baseline with advanced prostate cancer (HR = 1.30, 95% CI = 0.95-1.78) and prostate cancer mortality (HR = 1.52, 95% CI = 1.12-2.07) comparing BMI ≥35.0 kg/m2 with 21-22.9 kg/m2. When considering early adulthood and baseline BMI together, a 27% higher prostate cancer mortality risk (95% CI = 9% to 49%) was observed for men with BMI <25.0 kg/m2 in early adulthood and BMI ≥30.0 kg/m2 at baseline compared with BMI <25.0 kg/m2 in early adulthood and BMI <30.0 kg/m2 at baseline. Baseline waist circumference, comparing ≥110 cm with <90 cm, and waist-to-hip ratio, comparing ≥1.00 with <0.90, were associated with significant 14%-16% increases in high-grade prostate cancer risk and suggestive or significant 20%-39% increases in prostate cancer mortality risk. Height was associated with suggestive or significant 33%-56% risks of advanced or advanced restricted prostate cancer and prostate cancer mortality, comparing ≥1.90 m with <1.65 m. CONCLUSION: Our findings suggest that height and total and central adiposity in mid-to-later adulthood, but not early adulthood adiposity, are associated with risk of advanced forms of prostate cancer. Thus, maintenance of healthy weight may help prevent advanced prostate cancer.
引用
- Genkinger JM, Wu K, Wang M, et al. Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in The Pooling Project of Prospective Studies of Diet and Cancer. Ann Oncol. 2020. PMID: 31912782. doi:10.1016/j.annonc.2019.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。